BioNTech’s acquisition of CureVac in 2025 has been among the most notable pharmaceutical deals of the decade, drawing significant regulatory scrutiny due to underlying legal disputes and competitive concerns. The German biotech company agreed to pay $370 million to settle patent litigation with CureVac in the United States, a move that raised questions among regulators about BioNTech’s motives in acquiring a smaller competitor.

Regulatory authorities expressed concerns that the acquisition might lessen competition in the mRNA vaccine market, particularly given the ongoing copyright infringement lawsuit between the two companies. Observers noted that regulators generally aim to prevent deals that could consolidate market power excessively. BioNTech, however, was able to demonstrate through internal documentation that the acquisition was not intended to eliminate competition, a process described by legal advisors as "very complicated." The involvement of pharmaceutical giant GSK, which held a licensing agreement with CureVac, reportedly helped allay some regulatory concerns. As Florian Yilmaz, a legal expert on the transaction, pointed out, having a major player like GSK involved provided further reassurance to authorities evaluating the settlement and acquisition.

In a separate but related development illustrating the complexity of large pharmaceutical mergers, German drugmaker Merck completed its acquisition of the U.S.-based biotech firm SpringWorks Therapeutics for an equity value of $3.9 billion in 2025. Merck indicated that the deal would enhance its position in the rare tumor treatment market and support its expansion in the U.S. The acquisition prompted a notable increase in SpringWorks’ share price following early media reports.

Legal teams involved in such transactions face the challenging task of conducting thorough due diligence, particularly regarding the drug pipelines and regulatory approvals of the companies involved. In the case of Merck’s purchase of SpringWorks, special attention was given to Nirogacestat, a tumor-treating drug that had been approved in the United States but was still pending approval in the European Union at the time of acquisition. Legal advisors at the U.S. firm Sullivan & Cromwell, who represented Merck, structured the deal to address this regulatory discrepancy while ensuring compliance with antitrust laws. Since then, Nirogacestat has gained approval within the EU, smoothing the path for Merck’s broader commercialization efforts.

These transactions highlight the intricate balance pharmaceutical companies and their legal teams must strike between growth strategies, patent rights, and regulatory frameworks. Both the BioNTech-CureVac and Merck-SpringWorks deals underscore the critical role of due diligence and regulatory negotiation in complex cross-border pharmaceutical mergers and acquisitions amidst evolving market and legal landscapes.